WT1-specific T-cell responses in high-risk multiple myeloma patients undergoing allogeneic T cell-depleted hematopoietic stem cell transplantation and donor lymphocyte infusions.
about
Immunotherapy strategies for multiple myeloma: the present and the futureHuman heat shock protein-specific cytotoxic T lymphocytes display potent antitumour immunity in multiple myeloma.Analysis of the functional WT1-specific T-cell repertoire in healthy donors reveals a discrepancy between CD4(+) and CD8(+) memory formation.T-cell Exhaustion in Multiple Myeloma Relapse after Autotransplant: Optimal Timing of ImmunotherapyEvaluation of TCR repertoire diversity in patients after hematopoietic stem cell transplantation.CD34-Selected Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Relapsed, High-Risk Multiple Myeloma.Coinhibitory molecule PD-1 as a potential target for the immunotherapy of multiple myeloma.WT1 vaccination in acute myeloid leukemia: new methods of implementing adoptive immunotherapy.T cell-based targeted immunotherapies for patients with multiple myeloma.Beyond consolidation: auto-SCT and immunotherapy for plasma cell myeloma.Allogeneic stem cell transplantation in multiple myeloma: immunotherapy and new drugs.T-cell depleted allogeneic hematopoietic cell transplants as a platform for adoptive therapy with leukemia selective or virus-specific T-cells.Immunotherapy for Multiple Myeloma, Past, Present, and Future: Monoclonal Antibodies, Vaccines, and Cellular Therapies.Fast Cars and No Brakes: Autologous Stem Cell Transplantation as a Platform for Novel Immunotherapies.Adoptive Cell Therapy in Multiple Myeloma.Allogeneic stem cell transplantation for multiple myeloma: is there a future?Immune responses to WT1 in patients with AML or MDS after chemotherapy and allogeneic stem cell transplantation.Targeting Immune Checkpoints in Hematologic Malignancies.Allogeneic Hematopoietic Cell Transplantation for Myeloma: When and in Whom Does It Work.Highlights of the third International Conference on Immunotherapy in Pediatric Oncology.The emergence of WT1-specific T-cell responses following allogeneic T cell-depleted hematopoietic stem cell transplantation and low-dose donor lymphocyte infusions is associated with a graft-vs.- myeloma effect.Timing Is Everything: Combining Post-Transplantation Adoptive Cell Therapy and Tumor Vaccines.CAR T cell therapy for multiple myeloma: where are we now and where are we headed?Cancer-testis antigen 7 expression and immune responses following allogeneic stem cell transplantation for multiple myeloma.Allograft for Myeloma: Examining Pieces of the Jigsaw Puzzle.Wilms tumor 1/cytokeratin dual-color immunostaining reveals distinctive staining patterns in metastatic melanoma, metastatic carcinoma, and mesothelial cells in pleural fluids: an effective first-line test for the workup of malignant effusions.T-Cell Manipulation Strategies to Prevent Graft-Versus-Host Disease in Haploidentical Stem Cell Transplantation.
P2860
Q27021939-9CF54088-8E7B-4E5D-8D53-78ADBD5EAF11Q34052565-312517C5-9E74-4BA0-BA05-50AD5D85C438Q35889240-1973C0DA-1B8C-4DF7-8850-59151BF464DCQ36436758-65542036-B27A-43D7-A153-2E694DA450DCQ37044023-A06C753A-A2A8-4019-B64C-0F2FCC2DF002Q37155605-8EA1AAF4-8FCE-4FC0-A1B6-0BED4E884355Q38155039-FB736DCD-BC6A-4B31-9825-80326FB71FB5Q38187457-11A65D7F-E8DA-4E3E-A623-0A3ED55814E2Q38246639-10B3E1D0-85B7-48D9-8583-D4861D8EF894Q38370539-D8ED494A-0972-45A5-81B3-8FF8FB261517Q38417073-9A892AA0-3A06-49FD-A116-79691C32BC1BQ38514497-7342B7ED-1F30-4776-AC4C-61AB8F8F17CBQ38580545-041D1A63-DEEF-43DC-A7C0-C46AD4586BF0Q38612233-9BB07A23-2681-4055-9A70-AC306ACA8483Q38635138-D73FF2BD-1110-41E9-ADD7-7597CB7306D4Q38685796-4C9A9ACC-4D4D-4089-BE2B-862346F06454Q38947873-7A6F6DDE-F4DF-4606-92C1-F7D9697A052CQ38963420-A8104CAD-39B7-43B8-A3EF-7E0720ACC581Q39174731-2468E890-B49D-4D49-A771-4F984880642DQ39403785-61252D8A-1DBF-4FAA-81A4-9946F8307BC4Q41844605-ECA0954A-7BBE-4F23-8E37-09A17F1C4E04Q47147990-20746834-A264-4DC4-8FB0-A47FF5BEEF12Q47565827-439E9D0F-F014-4A41-94CF-62A8C1A38932Q49728427-97B1372A-DD29-4C68-8C6A-10EE77F7F98EQ50036381-BF95CB39-DD6D-4894-A7FF-86943B3887D4Q50465009-B0CB3846-2578-49B9-85F2-344B7341DF28Q55060181-57817CA0-2F67-48BD-8FA8-6B7BBFB4D227
P2860
WT1-specific T-cell responses in high-risk multiple myeloma patients undergoing allogeneic T cell-depleted hematopoietic stem cell transplantation and donor lymphocyte infusions.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
WT1-specific T-cell responses ...... nd donor lymphocyte infusions.
@en
WT1-specific T-cell responses ...... nd donor lymphocyte infusions.
@nl
type
label
WT1-specific T-cell responses ...... nd donor lymphocyte infusions.
@en
WT1-specific T-cell responses ...... nd donor lymphocyte infusions.
@nl
prefLabel
WT1-specific T-cell responses ...... nd donor lymphocyte infusions.
@en
WT1-specific T-cell responses ...... nd donor lymphocyte infusions.
@nl
P2093
P2860
P1433
P1476
WT1-specific T-cell responses ...... nd donor lymphocyte infusions.
@en
P2093
Achim A Jungbluth
Eleanor M Tyler
Guenther Koehne
Richard J O'Reilly
P2860
P304
P356
10.1182/BLOOD-2012-06-435040
P407
P577
2012-11-16T00:00:00Z